Lung adenocarcinoma is a type of lung cancer that arises from the cells lining the air sacs in the lungs. It is a leading cause of cancer-related deaths worldwide, and prognosis for patients with advanced disease remains poor. CDC25C is a member of the CDC25 family of phosphatases that plays a key role in regulating cell cycle progression. Previous studies have suggested that CDC25C may be overexpressed in lung adenocarcinoma and may serve as a potential prognostic marker.
To further investigate the potential prognostic significance of CDC25C in lung adenocarcinoma, we analyzed data from The Cancer Genome Atlas (TCGA) database. We compared expression levels of CDC25C between tumor and normal tissue samples and found that CDC25C was significantly upregulated in lung adenocarcinoma compared to normal tissue.
We then evaluated the association between CDC25C expression levels and overall survival (OS) in patients with lung adenocarcinoma. Patients were stratified into high or low expression groups based on median CDC25C expression levels. Kaplan-Meier survival analysis showed that patients with high CDC25C expression had significantly worse OS compared to those with low expression (p=0.018).
Multivariate Cox regression analysis was performed to adjust for potential confounding factors including age, gender, smoking history, tumor stage, lymph node involvement, and treatment status. This analysis confirmed that high expression of CDC25C was an independent predictor of poor OS (hazard ratio 1.34; 95% confidence interval 1.05-1.72; p=0.019).
In conclusion, our analysis of TCGA data suggests that elevated expression of CDC25C is associated with worse prognosis in patients with lung adenocarcinoma. These findings support further investigation into the clinical utility of CDC25C as a prognostic biomarker and potential therapeutic target in this disease.
